331 results about "Eccentric hypertrophy" patented technology

A small implantable stimulator(s) includes at least two electrodes for delivering electrical stimulation to surrounding tissue. The small stimulator provides means of stimulating the prostate with direct electrical current, such as relatively low-level direct current, without the need for external appliances during the stimulation session. The stimulator may be configured to be small enough to be implanted entirely within the prostate. Open- and closed-loop systems are disclosed.

The disclosure describes a method and a system that may be used to provide feedback on the progress of ablation therapy. The system includes a first needle that penetrates a target tissue to deliver radio frequency energy, with or without a conductive fluid, that heats and ablates the target tissue and a second needle that penetrates the target tissue and detects a tissue property indicative of the ablation progress. Temperature, impedance, or another parameter may be the tissue property detected and measured by the system. In addition, more than one sensor may be positioned on the first or second needle. The system may provide real-time monitoring of the tissue property or use the tissue property measurement to automatically terminate the ablation therapy. In particular, the system may be used to treat benign prostatic hypertrophy.

Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a beta1-adrenoceptor polypeptide and that are useful in the control and / or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of beta1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of beta1-adrenoceptor polypeptides in a host cell expressing beta1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.

This invention relates to methods for medical treatment of pathological conditions. More particularly, the invention relates to methods for using acoustic shock waves to treat a variety of pathological conditions such as plantar warts, deep bone bruises, prostate cancer, benign prostatic hypertrophy, urinary incontinence, and spinal cord injuries, including the reduction or removal of scar tissue to aid in spinal cord regrowth.

The present invention relates to compositions and methods for the detecting, treating, and empirically investigating the prostate. In particular, the present invention provides compositions and methods for using neuroligin biomarkers (e.g., NLGN-4Y) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy).

The invention relates to a Chinese medicinal preparation for treating a prostate disease, which is a medicament prepared from 70 raw material medicaments such as ginseng, deerhorn glue, medicinal indianmulberry root, common curculigo rhizome and the like. The medicament can be prepared into oral liquid, granules, powder, capsules, electuary, tablets or pills. A preparation method of the medicament comprises the following steps of: (1) preparing water extracting solution by the raw material medicaments; (2) preparing oral liquid by the water extracting solution; (3) drying, crushing and sieving the water extracting solution, and taking screening as medicinal extracting powder; and (4) preparing tablets, granules, pills or capsules from the medicinal extracting powder. The preparation method also can comprise the following steps of: (1) crushing and sieving the raw material medicaments, and taking the screening as medicinal powder; (2) disinfecting and sterilizing the medicinal powder to obtain raw powder; and (3) preparing tablets, granules, pills, electuary or capsules from raw powder. The adopted raw material medicaments are common Chinese medicaments, so the Chinese medicinal preparation has the advantages of low manufacturing cost, and nearly no toxic or side effects. The medicament has good curative effects on prostatitis, prostatic hypertrophy and prostatomegaly, and has obvious effect on prostate cancers.

A luminal stent is a tubular body formed by knitting a sole yarn of a bioresorbable polymer fiber, such as fiber of polylactic acid, polyglycol acid or a polylactic acid—polyglycol acid copolymer. When introduced into and attached to the inside of the vessel by a catheter fitted with a balloon, the tubular member may retain its shape for several weeks to several months after attachment and subsequently disappears by being absorbed into the living tissue. In this manner, the luminal stent is not left as a foreign matter semi-permanently in the living body without producing inflammation or hypertrophy in the vessel. There is also provided a method for attaching the luminal stent in the vessel.

Selective cellular ablation by electroporation, applicable, for example, to bulk tissue in the beating heart. Protocol parameters potentially induce tissue loss without thermal damage. Device and method are potentially applicable for myocardial tissue ablation to treat arrhythmias, obstructive hypertrophy, and / or to generate natural scaffolds for myocardial tissue engineering.

Novel piperzine derivatives substituted on one nitrogen by an aromatic system and on the other nitrogen by (2,5-dioxopyrrolidin)-1-yl) alkanes or (2,6-dioxopiperidin-1-yl) alkanes have been found to exhibit selective alpha 1A adrenergic activity. The compounds are useful for treatment of disease conditions, such as peripheral vascular disease, congestive heart failure, hypertension and especially benign prostatic hypertrophy.

The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and / or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and / or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.

The present invention relates to an agent for the treatment and / or prevention of pollakiuria comprising a compound having an antagonism to an EP1 receptor which is a prostaglandin E2 receptor subtype. A compound having an antagonism to an EP1 receptor antagonistically acts on an EP1 receptor which is a prostaglandin PGE2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and / or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).

This invention relates to a composition and method for treating diseases and disorders of the prostate such as prostatitis, benign prostatic hypertrophy, and prostate carcinoma. The prostate is treated by intraprostatic injection of a biodegradable sustained release formulation. By injecting the treatment substance directly into the prostate, improved treatment results are obtained with a much lower treatment substance dosage. Additionally, by incorporating the treatment substance into a biodegradable sustained release formulation, the need for frequent repetition of injections is eliminated.

The present invention identifies genes whose gene products are differentially expressed pressure overload of the heart. The invention provides methods for diagnosing or assessing an individual's susceptibility to heart failure from many etiologies, as well as the presence and severity of hypertrophy, chamber enlargement, or systolic heat failure. Also provided are therapeutic methods for treating a heart patient or methods for prophylactically treating an individual susceptible to heart failure. Additionally, the invention describes screening methods for identifying agents that can be administered to treat individuals that have suffered a heart attack or are at risk of heart failure.

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and / or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.

The present invention relates to the use of specific EGF-receptor antagonists for preparing a pharmaceutical composition for the prevention and / or treatment of benign prostatic hyperplasia and / or prostatic hypertrophy, a method for the treatment or prevention of benign prostatic hyperplasia / prostatic hypertrophy comprising administering an EGF-receptor antagonist of groups (A), (B) or (C), described herein optionally in combination with known compounds for the treatment of benign prostatic hyperplasia / prostatic hypertrophy, as well as associated pharmaceutical compositions.

Benzopyranone compounds having the following structure: wherein R1, X, Y and n are as defined here, are disclosed. The compounds of formula (I), wherein R1 is H, can be prepared by demethylation of the corresponding phenolic methyl ether. The compounds are useful for treating a bone-resorbing disease, cancer, arthritis or an estrogen-related condition such as breast cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, and adverse reproductive effects associated with exposure to environmental chemicals or natural hormonal imbalances.

The present invention provides an orthokeratological contact lens to be worn on a patient's cornea and methods for prescribing the same. The contact lens comprises a parabolic lens having an inner surface configured to face an epithelium of the patient's cornea, wherein the parabolic lens is adapted to reshape the cornea by way of epithelium and / or stromal tissue growth. In a pre-treatment configuration, an outer surface of the epithelium does not conform to the contours of the inner surface of the parabolic lens such that there exits a gap comprising a hypertrophy volume that is disposed between the epithelium and the parabolic lens.

Sterile injectable formulations, which comprise the following: (a) a ablation agent in an amount effective to cause necrosis of tissue, and (b) a biodisintegrable viscosity adjusting agent in an amount effective to render the formulation highly viscous, (c) an optional imaging contrast agent, (d) an optional therapeutic agent, and (e) an optional liquid selected from water and an organic solvent. Also described are novel prostatic ablation formulations, which comprise a prostatic ablation agent selected from free-radical generating ablation agents, oxidizing ablation agents and tissue fixing ablation agents. Further aspects of the invention relate to methods of treating a variety of diseases and conditions, including benign prostatic hypertrophy, in which above injectable formulations are injected into the tissue of a subject, optionally with the assistance of a non-invasive imaging technique.

The present compounds are intermediates for the preparation of quinoline derivatives and compositions having gonadotropin-releasing hormone antagonistic activity useful as propylactics or therapeutic agent for the prevention or treatment of several hormone dependent diseases, for example, a sex hormone dependent cancer (e.g. prostatic cancer, uterine or cervical cancer, breast cancer, pituitary adenoma), benign prostatic hypertrophy, myoma of the uterus, endometriosis, precocious puberty, amenorrhea, premenstrual syndrome, polycystic ovary syndrome and acne vulgaris; are effective as a fertility controlling agent in both sexes (e.g. a pregnancy controlling agent and a menstrual cycle controlling agent); can be used as a male or female contraceptive, as an ovulation-inducing agent; can be used as an infertility treating agent by using a rebound effect owing to a stoppage of administration thereof; and are useful for modulating estrous cycles in animals in the field of animal husbandry, as agents for improving the quality of edible meat or promoting the growth of animals, and as agents for promoting spawning in fish.

Compositions and methods are described for the treatment of prostatitis, benign prostatic hypertrophy, and prostate cancer. The compositions contain either aqueous extracts or dried mixtures of selenium- and zinc-enriched cannabis plant material, shiitake mushrooms, and maitake mushrooms. The compositions are effective in treating prostate disorders by alleviating pain and voiding symptoms, decreasing inflammation and prostate size, reducing cellular proliferation in prostate tissue, and / or reducing PSA levels to within the normal range of 0-4.

Disclosed herein are methods of treating a patient with benign hypertrophy of the prostate, comprising providing a compressible attenuation device that is moveable from a first, introduction configuration to a second, implanted configuration and attenuating a pressure change within the bladder by reversibly changing the volume of the attenuation device in response to the pressure change. In one embodiment, the attenuation device is advanced percutaneously into the bladder. In another embodiment, the attenuation device is positioned within the bladder to inhibit a decrease in compliance of the bladder wall as a consequence of the benign hypertrophy of the prostate.

To provide a medical energy irradiation apparatus which, having a simple and inexpensively manufacturable structure, enables a doctor using it in the heat curing of prostatic hypertrophy or the like to accurately and stably irradiate a prescribed site deep in a living body with a laser beam and, even if its observation window is smeared, to observe tissues of a living body. An inserting portion of the medical energy irradiation apparatus to be inserted into a living body according to the invention has an emitting portion for emitting a laser beam toward tissues of the living body; an observation window, provided near the tip of the inserting portion in its inserting direction, for observing the tissues of the living body; and a hollow pipe for supporting a supporting member, which supports the emitting portion, shiftably in the lengthwise directions of the inserting portion and feeding detergent to the observation window. Therefore, when the observation window is smeared, detergent can be fed to the observation window to remove the smear of the observation window.

The invention discloses a traditional Chinese medicine preparation for post-operation rehabilitation of cervicitis and cervical hypertrophy, which is prepared by the following traditional Chinese medicines in parts by weight: 2-8 parts of Chinese angelica, 1-5 parts of salvia miltiorrhiza bunge, 1-5 parts of drynaria rhizome, 1-5 parts of rhizoma pinelliae preparata, 1-4 parts of bletilla, 1-4 parts of dahurian angelica root, 2-8 parts of radix et rhizoma rhei, 1-5 parts of coptis chinensis, 1-6 parts of dandelion, 1-6 parts of elbow, 1-3 parts of dragon's blood, 1-5 parts of cape jasmine, 1-3 parts of ligusticum chuanxiong hort, 1-5 parts of borneol, 0.5-1.2 parts of frankincense, 0.5-1.2 parts of myrrh, 0.3-0.6 part of akebiaquinata, 1-3 parts of plantain seed, 1-3 parts of cortex moutan, 1-3 parts of polygonum aviculare, 1-3 parts of common cnidium fruit, 3-10 parts of polygonum cuspidatum, 1-5 parts of hairyvein agrimony, 1-3 parts of Chinese pulsatilla root, 1-4 parts of Chinese violet, 1-5 parts of dahurian patrinia herb and 1-3 parts of ginseng. The traditional Chinese medicine preparation is a pure traditional Chinese medicine preparation, which has little toxic and side effect, wide drug source, low cost and high curative effect and is proposed to be promoted and applied clinically.

The present invention provides an orthokeratological contact lens to be worn on a patient's cornea and methods for prescribing the same. The contact lens comprises a parabolic lens having an inner surface configured to face an epithelium of the patient's cornea, wherein the parabolic lens is adapted to reshape the cornea by way of epithelium tissue growth. In a pre-treatment configuration, an outer surface of the epithelium does not conform to the contours of the inner surface of the parabolic lens such that there exits a gap comprising a hypertrophy volume that is disposed between the epithelium and the parabolic lens.

The present invention relates to phenyl or heteroaryl amino alkane derivatives of formula (I) in which the groups Q1-Q4, Ar, and R1-R7 are as defined in the specification and claims. These materials are useful as active ingredients of pharmaceutical preparations. The phenyl or heteroaryl amino alkanes of the present invention have IP receptor antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with IP receptor antagonistic activity. Such diseases include urological diseases or disorders as follows: bladder outlet obstruction, overactive bladder, urinary incontinence, detrusor hyper-reflexia, detrusor instability, reduced bladder capacity, frequency of micturition, urge incontinence, stress incontinence, bladder hyperreactivity, benighn prostatic hypertrophy (BPH), prostatitis, urinary frequency, nocturia, urinary urgency, pelvic hypersensitivity, urethritis, pelvic pain syndrome, prostatodynia, cystitis, or idiophatic bladder hypersensitivity. The compounds of the present invention are also useful for treatment of pain including, but not limited to inflammatory pain, neuropathic pain, acute pain, chronic pain, dental pain, premenstrual pain, visceral pain, headaches, and the like; hypotension; hemophilia and hemorrhage; and inflammation, since these diseases also are alleviated by treatment with an IP receptor antagonist. The application claims the compounds, pharmaceutical compositions containing them, and methods of treatment using them.

Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and / or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.

Method is provided of treating or preventing hypertrophy, hypertension, myocardial ischemia, ischemic heart disease, myocardial infarction, congestive heart failure, organ ischemia, tissue ischemia, acute coronary syndrome, unstable angina, ischemia reperfusion injury, preventing death subsequent to myocardial infarction, cerebral infarction, contractile dysfunction subsequent to myocardial infarction, or arrhythmia in a mammal with low doses of pyridoxine, pyridoxal-5′phosphate, pyridoxal or pyridoxamine. Compositions and kits for said method is also included.

The present invention relates to new compounds of Formula (I): and pharmaceutically acceptable forms thereof, use of the compounds as α1a and / or α1d adrenoreceptor modulators, including use of a pharmaceutical composition, medicine or medicament comprising said compounds, a process to prepare said compounds and a method for treating an α1a and / or α1d adrenoreceptor mediated disorder.